ValiRx plc announced signature of an evaluation agreement with Imperial College London. This agreement enables ValiRx to evaluate research relating to novel therapeutic candidates for cancer treatment. The Agreement specifically focuses on investigating a lead series of dual-kinase inhibitor candidates that show promise in reversing resistance to current standard of care therapeutics in ovarian and other types of cancer.

Importantly, a similar approach has already been validated in clinical studies with other assets across a range of tumour types and it holds significant potential as a novel combination treatment. This project builds upon previous ground-breaking research led by Dr. Paula Cunnea, Group Leader at the Ovarian Cancer Action Research Centre, Division of Cancer, Faculty of Medicine, Imperial College London and the previous Imperial College Drug Discovery Centre. The evaluation process for this project is expected to take approximately 12 months, with the lead series scrutinised for mechanism of action and anti-cancer activity in combination with standard of care treatments in the Inaphaea BioLabs facility and will draw upon the skills of external collaborators.

Upon the conclusion of the evaluation, if milestones are met, the project will be considered for in-licensing on pre-agreed terms. This signifies an opportunity for ValiRx to further expand its portfolio of innovative cancer therapeutics.